Other adverse events · People with P. vivax malaria1
1 finding from 1 review
P. vivax parasitaemia detected > 30 days after starting primaquine · People with P. vivax malaria1
Primaquine three days probably leads to higher P. vivax parasitaemia detected > 30 days after starting primaquine compared with 14 days (moderate certainty).
1 finding from 1 review
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
Other adverse events · People with P. vivax malaria1
1 finding from 1 review
P. vivax parasitaemia detected > 30 days after starting primaquine · People with P. vivax malaria1
Primaquine seven days may leads to higher P. vivax parasitaemia detected > 30 days after starting primaquine compared with 14 days (low certainty).
1 finding from 1 review
Severe adverse events · People with P. vivax malaria1
1 finding from 1 review
Other adverse events · People with P. vivax malaria1
1 finding from 1 review
Treatment failure · Patients with presumed drug‐sensitive TB
1 finding from 1 review
Death from any cause · Patients with presumed drug‐sensitive TB
It is very uncertain whether fluoroquinolone substitution for ethambutol in a standard six month… changes death from any cause compared with standard regimen (very low certainty).
1 finding from 1 review
TB‐related death · Patients with presumed drug‐sensitive TB
It is very uncertain whether fluoroquinolone substitution for ethambutol in a standard six month… changes TB‐related death compared with standard regimen (very low certainty).
1 finding from 1 review
Sputum culture conversion at 8 weeks · Patients with presumed drug‐sensitive TB
It is very uncertain whether fluoroquinolone substitution for ethambutol in a standard six month… changes sputum culture conversion at 8 weeks compared with standard regimen (very low certainty).
1 finding from 1 review
Serious adverse events · Patients with presumed drug‐sensitive TB
It is very uncertain whether fluoroquinolone substitution for ethambutol in a standard six month… changes serious adverse events compared with standard regimen (very low certainty).
1 finding from 1 review
One or more adverse events · Patients with presumed drug‐sensitive TB
1 finding from 1 review
Treatment failure · Patients with presumed drug‐sensitive TB
1 finding from 1 review
Relapse · Patients with presumed drug‐sensitive TB
1 finding from 1 review
Death from any cause · Patients with presumed drug‐sensitive TB
Fluoroquinolone substitution for isoniazid in a standard six month… showed no clear difference in death from any cause compared with standard regimen (low certainty).
1 finding from 1 review
TB‐related death · Patients with presumed drug‐sensitive TB
Fluoroquinolone substitution for isoniazid in a standard six month… showed no clear difference in TB‐related death compared with standard regimen (low certainty).
1 finding from 1 review
Sputum culture conversion at 8 weeks · Patients with presumed drug‐sensitive TB
Fluoroquinolone substitution for isoniazid in a standard six month… showed no clear difference in sputum culture conversion at 8 weeks compared with standard regimen (low certainty).
1 finding from 1 review
Relapse · Patients with presumed drug‐sensitive TB
1 finding from 1 review
Serious adverse events · Patients with presumed drug‐sensitive TB
Fluoroquinolone substitution for isoniazid in a standard six month… showed no clear difference in serious adverse events compared with standard regimen (low certainty).
1 finding from 1 review